J. Safra Sarasin Holding AG Increases Stake in Intuitive Surgical, Inc. $ISRG

J. Safra Sarasin Holding AG increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 18.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,210 shares of the medical equipment provider’s stock after purchasing an additional 4,787 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Intuitive Surgical were worth $13,910,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ISRG. Riversedge Advisors LLC raised its stake in shares of Intuitive Surgical by 1.9% during the 4th quarter. Riversedge Advisors LLC now owns 901 shares of the medical equipment provider’s stock worth $510,000 after buying an additional 17 shares during the period. Fiduciary Financial Group LLC grew its stake in Intuitive Surgical by 2.1% in the 4th quarter. Fiduciary Financial Group LLC now owns 920 shares of the medical equipment provider’s stock valued at $521,000 after acquiring an additional 19 shares during the period. Prosperity Consulting Group LLC increased its holdings in Intuitive Surgical by 0.5% in the 3rd quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock worth $1,804,000 after acquiring an additional 19 shares in the last quarter. Sunburst Financial Group LLC raised its position in Intuitive Surgical by 4.3% during the fourth quarter. Sunburst Financial Group LLC now owns 485 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 20 shares during the period. Finally, WoodTrust Financial Corp raised its position in Intuitive Surgical by 0.5% during the fourth quarter. WoodTrust Financial Corp now owns 4,180 shares of the medical equipment provider’s stock worth $2,367,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: BMO Capital Markets upgraded Intuitive Surgical to strong-buy, which can help sentiment by signaling confidence in the stock’s long-term outlook. Zacks.com
• Positive Sentiment: Investor interest remains supported by expectations that July 16 results will show higher sales and EPS, with strong adoption of the da Vinci 5 surgical robot seen as a key growth driver. ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
• Neutral Sentiment: Evercore ISI cut its price target to $430 from $480 while keeping an In Line rating, suggesting the company still has growth potential but investors may be more cautious on near-term upside. Is Intuitive Surgical (ISRG) One Of MedTech’s Best AI Stock To Buy?
• Neutral Sentiment: Options traders are pricing in a wide range of outcomes for ISRG ahead of earnings, reflecting uncertainty around how the report and guidance could move the stock. Just How Much Risk Is Built Into ISRG Stock?
• Negative Sentiment: Investors are weighing possible margin pressure, which could limit enthusiasm even if revenue and earnings grow next quarter. ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 500 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $473.46, for a total value of $236,730.00. Following the sale, the director directly owned 239 shares of the company’s stock, valued at $113,156.94. The trade was a 67.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,169 shares of company stock worth $3,059,135 in the last ninety days. 0.60% of the stock is owned by insiders.

Intuitive Surgical Price Performance

ISRG opened at $406.78 on Monday. Intuitive Surgical, Inc. has a 1-year low of $396.68 and a 1-year high of $603.88. The firm has a market capitalization of $144.07 billion, a price-to-earnings ratio of 49.31, a price-to-earnings-growth ratio of 3.31 and a beta of 1.46. The company’s 50 day simple moving average is $422.09 and its two-hundred day simple moving average is $473.91.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter in the previous year, the company posted $1.81 EPS. The company’s revenue was up 23.0% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ISRG has been the subject of several research analyst reports. The Goldman Sachs Group set a $558.00 price target on shares of Intuitive Surgical in a research report on Wednesday, May 27th. HSBC cut their price objective on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. JPMorgan Chase & Co. decreased their target price on Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Truist Financial lowered their price target on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Finally, Evercore set a $430.00 price target on Intuitive Surgical in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $569.20.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.